Etanercept treatment in corticosteroid-dependent myasthenia gravis

J. Rowin, M. N. Meriggioli, E. Tüzün, S. Leurgans, P. Christadoss

Research output: Contribution to journalArticle

70 Scopus citations

Abstract

The authors report a prospective pilot trial of etanercept in corticosteroid-dependent autoimmune myasthenia gravis. Eleven patients were enrolled, with eight completing the 6-month trial. Two patients were withdrawn owing to disease worsening, and one patient was withdrawn because of an erythematous skin rash. Six of the eight patients who completed the trial improved, based on quantitative measures of muscle strength and lowering of corticosteroid requirement.

Original languageEnglish (US)
Pages (from-to)2390-2392
Number of pages3
JournalNeurology
Volume63
Issue number12
DOIs
StatePublished - Dec 28 2004

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Etanercept treatment in corticosteroid-dependent myasthenia gravis'. Together they form a unique fingerprint.

  • Cite this

    Rowin, J., Meriggioli, M. N., Tüzün, E., Leurgans, S., & Christadoss, P. (2004). Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology, 63(12), 2390-2392. https://doi.org/10.1212/01.WNL.0000147242.92691.71